Advertisement

Search Results

Advertisement



Your search for Matthew Stenger matches 76 pages

Showing 1 - 50


hematologic malignancies
lymphoma

Risk Model for Disease Progression in Asymptomatic Waldenström’s Macroglobulinemia

In a study reported in the Journal of Clinical Oncology, Bustoros et al developed a model for predicting risk of progression from asymptomatic Waldenström’s macroglobulinemia to symptomatic disease requiring treatment. The study involved 439 patients with asymptomatic...

solid tumors
hematologic malignancies

Standard Site-Specific Therapy Based on Gene-Expression Profiling vs Empirical Chemotherapy for Cancer of Unknown Primary

In a Japanese phase II trial reported in the Journal of Clinical Oncology, Hayashi et al found that standard site-specific treatment based on gene-expression profiling was not associated with better outcomes vs empirical paclitaxel and carboplatin in patients with cancer of unknown primary site....

hematologic malignancies
leukemia

MRD-Guided Azacitidine Treatment in Myelodysplastic Syndrome and Acute Myeloid Leukemia

In a German phase II trial (RELAZA2) reported in The Lancet Oncology, Platzbecker et al found that minimal residual disease (MRD)–guided treatment with azacitidine was successful in preventing hematologic relapse in patients with myelodysplastic syndrome (MDS) and acute myeloid leukemia...

hematologic malignancies

Effect of Donor Clonal Hematopoiesis of Indeterminate Potential in Allogeneic Hematopoietic Stem Cell Transplantation

In a study reported in the Journal of Clinical Oncology, Frick et al found that allogeneic hematopoietic stem cell transplantation (HSCT) from donors with clonal hematopoiesis of indeterminate potential (CHIP) appears safe and not associated with poorer survival when donors are older, related...

hematologic malignancies

Genomic Classification of Myeloproliferative Neoplasms and Integration in Predictive Models

In a study reported in The New England Journal of Medicine, Grinfeld et al identified distinct genomic subgroups among patients with myeloproliferative neoplasms that, when combined with clinical variables, offered the potential for individualized predictions of clinical outcomes. Study Details...

hematologic malignancies

Outcomes Associated With Mutation Persistence After HSCT for Myelodysplastic Syndrome

In a single-institution study reported in The New England Journal of Medicine, Duncavage et al found that mutation clearance after allogeneic hematopoietic stem cell transplantation (HSCT) was associated with better outcomes in patients with myelodysplastic syndrome. Study Details The study...

hematologic malignancies

Response to Ibrutinib in Symptomatic Untreated Waldenström’s Macroglobulinemia

In a study reported in the Journal of Clinical Oncology, Treon et al found that ibrutinib monotherapy was highly active in patients with previously untreated Waldenström’s macroglobulinemia, with better response in patients without CXCR4 mutation. Ibrutinib has been shown to be active in ...

solid tumors
hematologic malignancies

Monthly High-Dose Vitamin D and Cancer Risk

In a study reported in JAMA Oncology, Scragg et al found that monthly high-dose vitamin D supplementation, without calcium, was not associated with a reduced risk of developing cancer. Study Details The current analysis is a post hoc analysis of the Vitamin D Assessment (ViDA) study, which...

hematologic malignancies

Novel PI3Kδ Inhibitor in Relapsed or Refractory Hematologic Malignancies

In a phase I trial reported in The Lancet Oncology, Burris et al determined the phase II dose of the next-generation PI3Kδ inhibitor umbralisib and found evidence of the agent’s activity in relapsed or refractory hematologic malignancies. Umbralisib exhibits improved PI3K isoform...

hematologic malignancies

Cognitive Function After Hematopoietic Cell Transplantation for Hematologic Malignancy

In a prospective longitudinal study reported in the Journal of Clinical Oncology, Sharafeldin et al found that cognitive function after hematopoietic cell transplantation (HCT) for hematologic malignancy was impaired among those receiving myeloablative allogeneic HCT, with a delayed effect being...

hematologic malignancies

ASCO Clinical Practice Guideline Update: Platelet Transfusion for Patients With Cancer

As reported in the Journal of Clinical Oncology by Charles A. Schiffer, MD, of Karmanos Cancer Institute, Wayne State University School of Medicine, and colleagues, ASCO has issued a clinical practice guideline update on platelet transfusions in patients with cancer. The updated guideline replaces ...

hematologic malignancies

Anti–T-Lymphocyte Globulin and Chronic GVHD-Free Survival in Unrelated Myeloablative HCT

A double-blind phase III trial has shown no benefit of anti–T-lymphocyte globulin (ATLG) vs placebo on chronic graft-vs-host disease (GVHD)-free survival in patients undergoing human leukocyte antigen (HLA)-matched unrelated myeloablative hematopoietic cell transplantation (HCT). The study...

hematologic malignancies

Momelotinib vs Ruxolitinib in Janus Kinase Inhibitor–Naive Myelofibrosis

In the phase III SIMPLIFY-1 noninferiority trial reported in the Journal of Clinical Oncology, Mesa et al found that the selective Janus kinase (JAK) 1 and 2 inhibitor momelotinib was noninferior to ruxolitinib (Jakafi) in spleen response, but not symptom response, in JAK inhibitor–naive...

hematologic malignancies

Survey on Training in Geriatrics/Geriatric Oncology for Hematology-Oncology Fellows

Results from an ASCO-sponsored survey study indicate that despite professed interest in the area, most hematology-oncology fellows have inadequate training in geriatrics/geriatric oncology. These findings were reported in the Journal of Oncology Practice by Maggiore et al. Study Details The...

hematologic malignancies

Off-the-Shelf, Virus-Specific T Cells for Treating Viral Infections After Transplantation

In a phase II study reported in the Journal of Clinical Oncology, Tzannou et al found that use of off-the-shelf, broad-coverage, adoptively transferred, virus-specific T cells was feasible and effective in treating viral infections in patients who had undergone allogeneic hematopoietic stem cell...

hematologic malignancies

Association of Pretransplant Vitamin D Deficiency and Relapse in Myeloid Malignancies

A German retrospective study has found that pretransplantation vitamin D deficiency is associated with an increased risk of relapse in patients undergoing allogeneic stem cell transplantation (SCT) for myeloid malignancies. These findings were reported by Radujkovic et al in the Journal of Clinical ...

hematologic malignancies

Effect of Azithromycin on Airflow Decline–Free Survival After Allogeneic HSCT for Hematologic Malignancy

The French phase III ALLOZITHRO trial, stopped early due to excessive hematologic relapse in the azithromycin group, showed worse airflow decline–free survival with azithromycin vs placebo after hematopoietic stem cell transplantation (HSCT) for hematologic malignancy. The study findings were ...

hematologic malignancies

Italian Study of Serotherapy to Prevent GVHD in Pediatric Hematologic Malignancy

In an Italian phase III trial reported by Locatelli et al in The Lancet Oncology, a lower vs higher dose of rabbit anti–T-lymphocyte globulin (ATLG) was associated with a nonsignificantly greater incidence of acute graft-vs-host disease but better event-free and overall survival in children...

hematologic malignancies

Intestinal Microbiota and Relapse After Allogeneic Hematopoietic Cell Transplantation

A retrospective study has shown that the presence and abundance of a particular bacterial group in the intestinal microbiota are associated with a significantly lower risk of relapse or disease progression after allogeneic hematopoietic cell transplantation. The findings were reported by Peled et...

hematologic malignancies

Myeloablative vs Reduced-Intensity HCT for Acute Myeloid Leukemia and Myelodysplastic Syndromes

In a phase III trial reported in the Journal of Clinical Oncology, Scott et al found that myeloablative conditioning for allogeneic hematopoietic cell transplantation was associated with a reduced risk of relapse and a nonsignificant overall survival advantage vs reduced-intensity conditioning in...

hematologic malignancies

Study Finds Mutations in Myelodysplastic Syndrome Linked to Poorer Outcome After Stem Cell Transplantation

In a study reported in The New England Journal of Medicine, Lindsley et al found that a number of mutations present in patients with myelodysplastic syndrome (MDS) were associated with poorer clinical outcome after allogeneic hematopoietic stem cell transplantation (HSCT). Study Details The study ...

hematologic malignancies

Increased Morbidity and Mortality in HCT Survivors vs Other Cancer Survivors

In a study reported in the Journal of Clinical Oncology, Chow et al found that hematopoietic cell transplantation survivors had higher rates of morbidity and mortality compared with a matched population of patients with cancer not undergoing hematopoietic cell transplantation. The study involved...

hematologic malignancies
multiple myeloma

Study Finds Statin Use Associated With Reduced Mortality in Multiple Myeloma

Analysis of data from the Veterans Administration Central Cancer Registry, reported in the Journal of Clinical Oncology by Sanfilippo et al, showed that statin use was associated with a reduced risk of all-cause and multiple myeloma–specific mortality in patients with multiple myeloma....

hematologic malignancies
leukemia

Improved Event-Free Survival With Addition of Rituximab to Chemotherapy in B-Lineage Adult ALL

In the phase III GRAALL-2005 trial reported in The New England Journal of Medicine, Maury et al found that the addition of rituximab (Rituxan) to standard chemotherapy resulted in improved event-free survival in adult patients with B-lineage acute lymphoblastic leukemia (ALL). Study Details In...

hematologic malignancies

Good Outcome Reported With Unrelated-Donor Cord Blood Transplantation in Patients With Minimal Residual Disease

Survival with hematopoietic cell transplantation (HCT) from unrelated cord-blood donors was at least as good as that with HLA-matched unrelated donors and better than that with HLA-mismatched unrelated donors in patients with acute leukemia or myelodysplastic syndrome who had pretransplantation...

hematologic malignancies
leukemia

Is Extramedullary Disease at Diagnosis Prognostic in Adult Acute Myeloid Leukemia?

The presence of extramedullary disease at acute myeloid leukemia (AML) diagnosis was not an independent prognostic factor for worse survival, based on an analysis of data from the Eastern Cooperative Oncology Group–American College of Radiology Imaging Network (ECOG-ACRIN) reported by Ganzel...

hematologic malignancies
lymphoma

Higher Baseline Metabolic Tumor Volume May Predict Poorer Outcome in Patients With High Tumor Burden Follicular Lymphoma

In a pooled analysis reported in the Journal of Clinical Oncology, Meignan et al found that higher baseline total metabolic tumor volume measured by 18F-fluorodeoxyglucose (18F-FDG) positron-emission tomography–computed tomography (FDG PET-CT) was associated with poorer outcome in patients...

hematologic malignancies
lymphoma

High Cumulative Burden of Cardiovascular Morbidity in Young Survivors of Hodgkin Lymphoma

In an analysis from the St. Jude Lifetime Cohort Study reported in The Lancet Oncology, Bhakta et al found a high cumulative burden of cardiovascular morbidity among pediatric, adolescent, and young adult survivors of Hodgkin lymphoma. Study Details The study involved data from 670 survivors of...

hematologic malignancies

Ipilimumab Appears Active in Relapsed Hematologic Cancer After Allogeneic HSCT

In a phase I/Ib study reported in The New England Journal of Medicine, Davids et al found that ipilimumab (Yervoy; at a dose of 10 mg/kg) produced responses, including complete responses, in patients with relapsed hematologic cancer after allogeneic hematopoietic stem cell transplantation (HSCT)....

hematologic malignancies
lymphoma

CNS-IPI for CNS Relapse in Diffuse Large B-Cell Lymphoma

As reported in the Journal of Clinical Oncology, Schmitz et al have developed and validated a risk score for CNS relapse—the Central Nervous System International Prognostic Index (CNS-IPI)—in patients with diffuse large B-cell lymphoma (DLBCL) treated with R-CHOP (rituximab [Rituxan]...

hematologic malignancies
lymphoma

Analysis Indicates Continued Risk of Relapse Independent of Treatment Modality in Limited-Stage DLBCL

In an analysis of data from SWOG studies reported in the Journal of Clinical Oncology, Stephens et al found as continued risk of relapse among patients with limited-stage diffuse large B-cell lymphoma (DLBCL) irrespective of whether they received CHOP (cyclophosphamide, doxorubicin, vincristine,...

hematologic malignancies
lymphoma

Early Results Find Pembrolizumab Active in Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure

Findings in a classical Hodgkin lymphoma cohort in the phase Ib KEYNOTE-013 trial, reported by Armand et al in the Journal of Clinical Oncology, indicate that pembrolizumab (Keytruda) is active in patients with disease progressing on or after brentuximab vedotin (Adcetris) treatment. Study Details ...

hematologic malignancies
multiple myeloma

Long-Term Benefit of Lenalidomide/Dexamethasone Reported in High-Risk Smoldering Multiple Myeloma

As reported by Mateos et al in The Lancet Oncology, long-term follow-up in the phase III QuiRedex trial indicates continued benefit of lenalidomide (Revlimid)/dexamethasone vs observation in preventing disease progression in patients with high-risk smoldering multiple myeloma. Study Details In...

hematologic malignancies
multiple myeloma

Obesity Linked to Increased Risk of Multiple Myeloma Mortality in African Americans

Obesity may be associated with an increased risk for death from multiple myeloma in African Americans, according to a study reported by Sonderman et al in the Journal of the National Cancer Institute. Multiple myeloma incidence and mortality rates have been reported to be twice as high among...

hematologic malignancies
lymphoma

Adding Obinutuzumab to Bendamustine Improves Progression-Free Survival in Rituximab-Refractory NHL

In the phase III GADOLIN trial reported in The Lancet Oncology, Sehn et al found that adding the anti-CD20 antibody obinutuzumab (Gazyva) to bendamustine (Bendeka, Treanda) increased progression-free survival in patients with rituximab-refractory indolent non-Hodgkin lymphoma (NHL). Outcomes in...

hematologic malignancies
leukemia

Genomic Classification and Outcome in Acute Myeloid Leukemia

As reported in The New England Journal of Medicine, Papaemmanuil et al have identified 11 genomic subgroups in acute myeloid leukemia (AML) associated with distinct diagnostic features and clinical outcomes. AML Subgroups The study included analysis of driver mutations in 111 cancer genes and...

hematologic malignancies
leukemia

Study Finds Inotuzumab Ozogamicin Improves Outcomes vs Standard Therapy in Relapsed/Refractory ALL

In a phase III trial reported in The New England Journal of Medicine, Kantarjian et al found that treatment with the antibody-drug conjugate inotuzumab ozogamicin resulted in a greater complete remission rate and improved overall survival vs standard therapy in patients with relapsed/refractory...

hematologic malignancies
issues in oncology

Four-Biomarker Panel Identified for Chronic Graft-vs-Host Disease

In a study reported in the Journal of Clinical Oncology, Yu et al identified a four-biomarker panel that was predictive of chronic graft-vs-host disease after allogeneic hematopoietic cell transplantation. Discovery Cohort In the study, a quantitative proteomics approach was used to compare...

hematologic malignancies
lymphoma

Enzastaurin Fails to Improve Outcomes in Patients With High-Risk DLBCL in Remission After Chemotherapy

Crump et al found no disease-free survival benefit of maintenance therapy with the selective protein kinase Cb (PKCb) inhibitor enzastaurin in patients with diffuse large B-cell lymphoma (DLBCL) who were in complete remission and at high risk of relapse after first-line chemotherapy, according to a ...

hematologic malignancies
leukemia

5-Year Results of DASISION Trial of Dasatinib vs Imatinib in CML

As reported in the Journal of Clinical Oncology by Cortes et al, the final 5-year results of the DASISION trial support the safety and efficacy of dasatinib (Sprycel) as first-line treatment in patients with chronic myeloid leukemia (CML) in chronic phase. Initial results in the trial led to...

hematologic malignancies
leukemia

International Prognostic Index for Patients With Chronic Lymphocytic Leukemia

The International Chronic Lymphocytic Leukemia–International Prognostic Index (CLL-IPI) working group has developed an IPI for patients with chronic lymphocytic leukemia based on a meta-analysis of individual patient data, as reported in The Lancet Oncology. Study Details The meta-analysis...

hematologic malignancies
leukemia

Venetoclax Produces High Response Rate in Relapsed or Refractory CLL With 17p Deletion

In a phase II study reported in The Lancet Oncology, Stilgenbauer et al found that the BCL2 inhibitor venetoclax (Venclexta) produced a high response rate in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) with the 17p deletion (del [17p]). The study supported the recent...

hematologic malignancies
leukemia

Donor Epstein-Barr Virus Status Affects Risk for Graft-vs-Host Disease but Not Survival in Acute Leukemia After HSCT

Positive donor Epstein-Barr virus (EBV) serostatus increases the risk for graft-vs-host disease but does not affect relapse-free or overall survival among patients with acute leukemia receiving allogeneic hematopoietic stem cell transplantation (allo-HSCT), according to a study from the Acute...

hematologic malignancies
myelodysplastic syndromes

Prognostic Scoring System for Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome

As reported in the Journal of Clinical Oncology, Shaffer et al have developed a prognostic scoring system for patients undergoing allogeneic hematopoietic cell transplantation for myelodysplastic syndrome. Study Details The study involved data from 2,133 patients with myelodysplastic syndrome in...

hematologic malignancies
multiple myeloma

International Myeloma Working Group Recommendations for Myeloma-Related Renal Impairment

International Myeloma Working Group recommendations for the diagnosis and management of myeloma-related renal impairment were recently reported by Dimopoulos et al in the Journal of Clinical Oncology. Recommendations were based on review of published data through December 2015. Key recommendations...

hematologic malignancies
lymphoma

Italian Study Suggests Benefit of Interim PET Response–Adapted Therapy in High-Risk Advanced Hodgkin Lymphoma

The phase II portion of the Italian HD0801 study suggests that treatment based on positron-emission tomography (PET) performed early in first-line therapy for advanced Hodgkin lymphoma may improve outcome in patients at risk of first-line treatment failure. Zinzani et al reported their findings in...

solid tumors
hematologic malignancies
issues in oncology
survivorship

Increased Risk of Cardiovascular Disease Among Survivors of Some Adult-Onset Cancers

In a study using managed-care organization data reported in the Journal of Clinical Oncology, Armenian et al found that survivors of adult-onset multiple myeloma, non-Hodgkin lymphoma, lung/bronchus cancer, and breast cancer had an increased risk for subsequent cardiovascular disease. Study...

hematologic malignancies

Antithymocyte Globulin Reduces Need for Immunosuppressants After Hematopoietic Cell Transplantation From Unrelated Donors

In a phase III trial reported in The Lancet Oncology, Walker et al found that treatment with antithymocyte globulin reduced the need for immunosuppressive therapy in patients with hematologic malignancies receiving hematopoietic cell transplantation from unrelated donors. Study Details In this...

hematologic malignancies
lymphoma
survivorship

Dutch Study Shows Increased Risk of Second Cancer for Survivors of Hodgkin Lymphoma During Long-Term Follow-up

In a Dutch study reported in The New England Journal of Medicine, Schaapveld et al found that survivors of Hodgkin lymphoma treated between 1965 and 2000 were at a 4.6-fold greater risk of second cancer vs the general population during long-term follow-up. There was no significant difference in the ...

breast cancer
hematologic malignancies
leukemia
sarcoma

Increased Breast Cancer Risk Reported in Childhood Sarcoma and Leukemia Survivors With No History of Chest Radiotherapy

In an analysis of the Childhood Cancer Survivor Study reported in the Journal of Clinical Oncology, Henderson et al found that childhood survivors of sarcoma and leukemia with no history of chest radiotherapy were at an increased risk of breast cancer. Increased Risk The study included data from...

Advertisement

Advertisement



;
Advertisement